I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

Corporate Breaking News

Home : I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

Oct 04 2019	I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced...


Source:https://www.prnewswire.com:443/news-releases/i-mab-biopharma-receives-ind-approval-in-china-for-proprietary-cd73-antibody-tjd5-300931152.html

Related News
» Albert Bremser, Senior Consultant, NERA Economic Consulting to Lost Profits: Principles, Methods and Strategies to Prove and Defend Damages » STL and Frogfoot Partner to Bring Affordable Broadband Connectivity to 20,000 Homes in Soweta, Johannesburg